Skip to main content

Table 2 The change of drug price index for centralized purchased drugs and alternative drugs pre- and post-“4 + 7” policy

From: Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

 

LP

PP

FP

Pre-

Post-

GR (%)

Pre-

Post-

GR (%)

Pre-

Post-

GR (%)

“4 + 7” List drugs

Mean

0.98

0.40

−58.95

0.98

0.39

−60.68

0.48

0.08

−83.38

 SD

0.02

0.07

0.01

0.07

0.02

0.03

 Min

0.95

0.35

0.96

0.34

0.46

0.06

 Max

1.00

0.60

0.99

0.59

0.50

0.18

Alternatives

 Mean

0.99

0.97

−2.30

0.99

0.97

−2.11

0.49

0.47

−4.34

 SD

0.01

0.02

0.01

0.02

0.01

0.02

 Min

0.98

0.95

0.97

0.95

0.48

0.45

 Max

1.02

1.00

1.00

1.00

0.51

0.50

Overall

 Mean

0.98

0.63

−35.83

0.98

0.58

−41.49

0.48

0.18

−62.21

 SD

0.01

0.05

0.01

0.06

0.01

0.03

 Min

0.97

0.60

0.97

0.52

0.47

0.16

 Max

1.00

0.77

1.00

0.72

0.50

0.28

  1. LP, Laspeyres Price Index; PP, Paasche Price Index; FP, Fisher Price Index; Pre-, pre-“4 + 7” policy, i.e. July 2018 to February 2019; Post-, post-“4 + 7” policy, i.e. March 2019 to December 2019
  2. GR growth rate, SD standard deviation